• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

CANERTINIB Drug Record

  • Summary
  • Interactions
  • Claims
  • CANERTINIB chembl:CHEMBL31965 Antineoplastic

    Alternate Names:

    CI-1033
    CANERTINIB
    PD 183805
    CI 1033
    chembl:CHEMBL31965
    chemidplus:267243-28-7
    drugbank:05424
    pubchem.compound:156414

    Drug Info:

    Drug Class Kinase Inhibitors
    (3 More Sources)

    Publications:

    Wang et al., 2006, HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors., Cancer Cell
    Christensen et al., 2005, Plasma vascular endothelial growth factor and interleukin-8 as biomarkers of antitumor efficacy of a prototypical erbB family tyrosine kinase inhibitor., Mol. Cancer Ther.
    Ward RA et al., 2013, Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR)., J Med Chem
    Li et al., 2008, BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models., Oncogene
    Hur W et al., 2008, Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase., Bioorg Med Chem Lett
  • CANERTINIB   BMX

    Interaction Score: 5.89

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18667312


    Sources:
    DTC

  • CANERTINIB   EGFR

    Interaction Score: 0.32

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    23930994 18408761


    Sources:
    DTC MyCancerGenome CIViC TTD

  • CANERTINIB   CXCL8

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15956251


    Sources:
    NCI

  • CANERTINIB   ERBB2

    Interaction Score: 0.24

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Indication/Tumor Type Advanced Solid Tumor
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    16843263


    Sources:
    MyCancerGenome JAX-CKB TTD

  • CANERTINIB   AKT1

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • CANERTINIB   MTOR

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CANERTINIB   YES1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MyCancerGenome: CANERTINIB

    • Version: 20-Jun-2017

    Alternate Names:
    CANERTINIB Generic Name

    Drug Info:
    Drug Class Kinase Inhibitors

    Publications:

  • NCI: CI-1033

    • Version: 14-September-2017

    Alternate Names:
    C1880 NCI drug code

    Drug Info:

    Publications:
    Christensen et al., 2005, Plasma vascular endothelial growth factor and interleukin-8 as biomarkers of antitumor efficacy of a prototypical erbB family tyrosine kinase inhibitor., Mol. Cancer Ther.

  • DTC: CANERTINIB

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL31965 ChEMBL Drug ID

    Drug Info:

    Publications:
    Hur W et al., 2008, Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase., Bioorg Med Chem Lett
    Ward RA et al., 2013, Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR)., J Med Chem

  • JAX-CKB: Canertinib

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Wang et al., 2006, HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors., Cancer Cell

  • CIViC: CANERTINIB

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Li et al., 2008, BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models., Oncogene

  • TTD: CI-1033

    • Version: 2020.06.01

    Alternate Names:
    D0YB3W TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL31965

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21